Industry
Biotechnology
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Loading...
Open
72.11
Mkt cap
12B
Volume
2.9M
High
72.11
P/E Ratio
-11.84
52-wk high
80.53
Low
65.97
Div yield
N/A
52-wk low
21.92
Portfolio Pulse from Benzinga Insights
August 26, 2024 | 2:00 pm
Portfolio Pulse from Benzinga Newsdesk
August 23, 2024 | 5:56 pm
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 1:10 pm
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 10:35 am
Portfolio Pulse from Benzinga Newsdesk
August 09, 2024 | 5:45 pm
Portfolio Pulse from Benzinga Newsdesk
August 09, 2024 | 2:26 pm
Portfolio Pulse from Benzinga Newsdesk
August 09, 2024 | 12:36 pm
Portfolio Pulse from Benzinga Insights
August 08, 2024 | 7:31 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 12:19 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 11:09 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.